Table 6.
Direct and indirect effects of criteria in each cluster
| Criteria | (R + C) | (R − C) | |
|---|---|---|---|
| CTR1: Scientific approach and technology used | |||
| 7 | Coverage of different technologies | 15.01012977 | − 1.069650646 |
| 11 | Individuals included in vaccine trials | 15.71545595 | 0.767706886 |
| 13 | Vaccine regulation | 15.3660784 | − 0.732049227 |
| 21 | Sourcing of appropriate expertise | 13.30900535 | 1.327549866 |
| 41 | No serious side effects | 15.08626407 | − 0.293556879 |
| CTR2: Speed of delivery | |||
| 52 | Speed of processes | 19.71803677 | − 1.228229698 |
| 53 | Progress in clinical trials | 19.11957218 | 0.018927311 |
| 54 | Estimated time to market in 2020 and 2021 | 17.89725139 | 0.309802989 |
| 55 | Application for marketing authorizations | 19.78167492 | 0.640193116 |
| 56 | Reduced outbreaks | 19.56403032 | 0.682856467 |
| 57 | Avoidance of misinformation | 19.17961015 | − 1.290898621 |
| 59 | Extensive testing of safety and effectiveness | 19.39656537 | 0.867348437 |
| CTR3: Cost | |||
| 19 | Rigorous analysis of results | 12.78867858 | 1.619404715 |
| 61 | Production cost | 12.89344839 | 0.502080687 |
| 62 | Payment terms | 13.80189928 | − 0.691757682 |
| 63 | Payment schedule | 12.72568174 | − 0.553306233 |
| 104 | Testing and evaluation before licensing by Food and Drug Administration | 12.36781638 | − 0.876421487 |
| CTR4: Liability and risk sharing | |||
| 67 | Benefits offered by financing provided | 16.65697865 | − 0.84739254 |
| 68 | Final purchase conditions | 15.86153375 | − 0.248925465 |
| 69 | Liability terms | 17.65648392 | 0.219894345 |
| 70 | Commitment to regulators | 15.94897471 | − 0.583497016 |
| 72 | Vaccination ethics | 17.35307759 | 0.014091765 |
| 75 | Vaccine injury compensation | 15.58030584 | − 0.122424521 |
| 78 | Post-research immunization schedule | 13.42471281 | 1.568253432 |
| CTR5: Ability to supply sufficient quantities through production capacity development | |||
| 43 | Global production capacity | 13.04860795 | − 0.147709773 |
| 44 | Production capacity without disruptions | 14.57094816 | − 0.12889826 |
| 46 | Mitigation of supply chain disruptions | 13.52509107 | − 0.679156463 |
| 47 | Consistent ability to manufacture | 14.263633 | − 0.51660328 |
| 48 | Vaccine production facilities | 14.3857391 | 0.871495514 |
| 49 | Safest vaccine supply to date | 13.2375538 | − 0.516982925 |
| 50 | Every vaccine batch tested | 11.90515624 | 1.117855186 |
| CTR6: Global solidarity | |||
| 85 | Vaccine tests in vulnerable populations | 21.80083619 | − 0.166287667 |
| 91 | Vaccine supply for world’s poorest countries | 21.96719102 | − 1.481635453 |
| 92 | Equitable access to vaccines in emergencies | 21.75202149 | 1.92394612 |
| 93 | Vaccine provision for financially disadvantaged individuals | 21.82751528 | 0.092452284 |
| 94 | No racism or other forms of discrimination | 21.22157512 | − 0.879315539 |
| 102 | Education about vaccination value | 22.24485781 | 0.375208736 |
| 103 | Vaccination status checks among school children | 22.80895714 | 0.13563152 |